A 42-year-old white woman, with chronic, discoid lupus erythematosus of 12 years' duration, was found to be intolerant (acute gastroenteritis) of all previously tried antimalarials. Because of recent reports1 on the use of amodiaquin (Camoquin) it was felt judicious to institute such therapy in this patient. The patient presented multiple, well-defined, atrophic, depigmented scars of the face, coupled with active erythematous, defined scaling plaques. Blood studies on many occasions were essentially negative. Amodiaquin therapy was instituted. Within 10 days of the institution of such therapy total resolution of all cutaneous lesions had occurred and dosage was reduced to maintenance levels. Approximately 18 days after the onset of amodiaquin therapy the patient developed a gradually progressive icterus type of pigmentation noted in all skin areas and the sclera. Associated with this was marked lethargy, anorexia, amenorrhea, and partial blindness. Studies at this time